about
Effectiveness of UNAIDS targets and HIV vaccination across 127 countries.Complex immune correlates of protection in HIV-1 vaccine efficacy trials.A recombinant multi-epitope protein MEP1 elicits efficient long-term immune responses against HIV-1 infection.Nanoparticles decorated with viral antigens are more immunogenic at low surface density.Synthetic biology approach for the development of conditionally replicating HIV-1 vaccine.Time-course, negative-stain electron microscopy-based analysis for investigating protein-protein interactions at the single-molecule level.Will Systems Biology Deliver Its Promise and Contribute to the Development of New or Improved Vaccines? Seeing the Forest Rather than a Few Trees.Effects of Mutations on Replicative Fitness and Major Histocompatibility Complex Class I Binding Affinity Are Among the Determinants Underlying Cytotoxic-T-Lymphocyte Escape of HIV-1 Gag Epitopes.Antibody therapies for the prevention and treatment of viral infections.Novel Therapeutic Approach for Inhibition of HIV-1 Using Cell-Penetrating Peptide and Bacterial Toxins.HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees.Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.Development of a Live Recombinant BCG Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Gag Using a pMyong2 Vector System: Potential Use As a Novel HIV-1 Vaccine.HIV Vaccination: A Roadmap among Advancements and Concerns.Mathematical Analysis of Viral Replication Dynamics and Antiviral Treatment Strategies: From Basic Models to Age-Based Multi-Scale Modeling
P2860
Q30400132-2DE56842-5D61-41FE-9BB1-AD9115917072Q39108779-867ED53B-14FD-4666-8AC6-62B3AE83E58AQ40298230-BFC8C792-24EF-419B-A09B-512EE19259E4Q40393904-FFCAF48A-1D34-4BD3-AC7E-F8BC5D61C62CQ41923238-53D3602E-5BA2-4DCB-90BB-2A495895D435Q41925648-8909231A-2241-474A-A500-426DE5DCF648Q46066194-16A5D9C0-DB3A-4A03-9BBC-E6A4E30F98CEQ46652739-18CB23E3-94E6-462D-8C17-C429D1672457Q47143843-61F1EEC5-44E9-4A2E-B70B-9A68584B3595Q47144668-422020EE-B672-467F-AE38-E8C774852D58Q47547483-DCDDB017-C652-4527-9696-3D62B0AEDA04Q52561260-13322B7C-93FA-4BD2-9D2D-016BDEEB6375Q52595182-DE0ED62B-9C44-4E0B-9E83-DE49C24AACADQ54232567-F71924ED-4289-422E-B192-4989FC09833AQ56000943-844E0D77-CD22-4384-9F5A-6DB5785FB26F
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Approaches to preventative and therapeutic HIV vaccines
@ast
Approaches to preventative and therapeutic HIV vaccines
@en
Approaches to preventative and therapeutic HIV vaccines
@nl
type
label
Approaches to preventative and therapeutic HIV vaccines
@ast
Approaches to preventative and therapeutic HIV vaccines
@en
Approaches to preventative and therapeutic HIV vaccines
@nl
prefLabel
Approaches to preventative and therapeutic HIV vaccines
@ast
Approaches to preventative and therapeutic HIV vaccines
@en
Approaches to preventative and therapeutic HIV vaccines
@nl
P2093
P2860
P1476
Approaches to preventative and therapeutic HIV vaccines
@en
P2093
Barbara Ensoli
Erica Lazarus
Fatima Laher
Glenda E Gray
P2860
P356
10.1016/J.COVIRO.2016.02.010
P407
P577
2016-04-01T00:00:00Z